Author

F. De Paolis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Aureli· 1 shared A. Ottaviani· 1 shared A. Reggio· 1 shared A. Venditti· 1 shared C. Cenciarelli· 1 shared C. Cirillo· 1 shared C. Fuoco· 1 shared C. Gargioli· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Aureli

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

3D bioprinting directly affects proteomic signature and myogenic maturation in muscle pericytes-derived human myo-substitute.

A. Reggio, C. Fuoco, F. De Paolis, S. Testa, N. Celikkin, S. Bernardini, J. Baldi, R. Biagini, D. Seliktar, C. Cirillo, P. Grumati, S. Cannata, M. Costantini, C. Gargioli

This study shows that 3D bioprinting enhances myogenic differentiation and proteomic changes in muscle pericytes, leading to improved muscle regeneration in vivo.

bioRxiv · Jul 10, 2023 · PreprintBioengineering

ANTIBODY-INDEPENDENT ANTITUMOR EFFECTS OF CD32A-CHIMERIC RECEPTOR T CELLS: IMPLICATIONS FOR BREAST CANCER PROGNOSIS AND TREATMENT.

G. Sconocchia, G. Lanzilli, V. Cesarini, D. A. Sivestris, R. Arriga, K. Rezvani, S. Caratelli, K. Chen, J. Dou, C. Cenciarelli, G. Toietta, S. Baldari, T. Sconocchia, F. De Paolis, A. Aureli, , G. C. Spagnoli

This study shows CD32A-chimeric receptor T cells can identify CD32A ligands, predict breast cancer sensitivity, and improve prognosis without antibodies.

bioRxiv · Dec 22, 2021 · PreprintImmunology